For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Inteferon-alpha (IFN-a) is a cytokine involved in innate immune response against viral infection. It is produced by leukocytes and other cell types like plasmacytoid dendritic cells. There are many IFN-a subtypes, with molecular weights ranging from 15 to 21 kDa. They all possess the same antiviral activity, but may differ in their relative biological activities. IFN-a also exhibits several antiproliferative and antitumor activities, making it one of the most used cytokine treatments in cancer patients suffering from hairy cell leukemia, renal carcinoma, Kaposi’s sarcoma, and other malignancies. Under physiological conditions, a low level of IFN-a is detected. However, its production is markedly enhanced during infections and various pathological situations, making IFN-a a major disease marker.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.